Here are the 424B prospectus supplements from Kalaris Therapeutics, Inc. (KLRS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow KLRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLRS filings page.
Kalaris Therapeutics, Inc. registered up to $100,000,000 of common stock for sale through an at-the-market program with TD Securities (USA) LLC (TD Cowen). The prospectus permits sales from time to time at market prices, including negotiated block trades or sales on The Nasdaq Global Market.
The prospectus states 22,902,418 shares were outstanding as of December 31, 2025 and discloses an illustrative assumed offering price of $5.79 per share used to show dilution. Compensation to TD Cowen is up to 3.0% of gross proceeds and the company may sell shares to TD Cowen as principal. Net proceeds are intended for general corporate purposes including R&D, clinical development, working capital and potential acquisitions.
Kalaris Therapeutics, Inc. is registering for resale up to 5,000,000 shares of its common stock, consisting of 4,200,000 outstanding shares held by selling stockholders and 800,000 shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from resales, but will receive cash if pre-funded warrants are exercised at an exercise price of $0.0001 per share. The registration implements registration rights granted in connection with a December 17, 2025 private placement in which the company raised aggregate gross proceeds of approximately $50.0 million through the sale of common stock and pre-funded warrants. Resales may occur from time to time in various manners described under the plan of distribution; certain exercise and beneficial ownership limits (a 4.99% default cap, up to 19.99% if elected) apply to the pre-funded warrants.